Page last updated: 2024-11-10

tak 456

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

TAK 456: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3002973
CHEMBL ID4852565
SCHEMBL ID4681272
MeSH IDM0383792

Synonyms (14)

Synonym
tak-456
2-imidazolidinone, 1-[(1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]-3-[4-(1h-tetrazol-1-yl)phenyl]-
1-[(1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1,2,4-triazol-1-yl)propyl]-3-[4-(tetrazol-1-yl)phenyl]imidazolidin-2-one
tak 456
1-[(2r,3r)-3-(2,4-difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-3-[4-(tetrazol-1-yl)phenyl]imidazolidin-2-one
JTNIHNJCRCYZSU-IVZQSRNASA-N
1-[(1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]-3-[4-(1h-tetrazol-1-yl)phenyl]-2-imidazolidinone
SCHEMBL4681272
1-[(1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl]-3-[4-(1h-1-tetrazolyl)phenyl]-2-imidazolidinone
2-imidazolidinone, 1-(2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl)-3-(4-(1h-tetrazol-1-yl)phenyl)-, (r-(r*,r*))-
181869-54-5
1-((1r,2r)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1h-1,2,4-triazol-1-yl)propyl)-3-(4-(1h-1-tetrazolyl)phenyl)-2-imidazolidinone
PD160803
CHEMBL4852565
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID1872515Antifungal activity against Aspergillus fumigatus TIMM1728 assessed as inhibition of fungal growth incubated for 20 hrs2022European journal of medicinal chemistry, Mar-05, Volume: 231Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID1872516Antifungal activity against Aspergillus fumigatus IFO6344 assessed as inhibition of fungal growth incubated for 20 hrs2022European journal of medicinal chemistry, Mar-05, Volume: 231Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID1872507In vivo antifungal activity against Candida albicans infected in CDF1 mouse treated po or iv 2 hrs after infection twice daily for 2 days measured on day 102022European journal of medicinal chemistry, Mar-05, Volume: 231Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID1872511Antifungal activity against Candida albicans TIMM1756 assessed as inhibition of fungal growth incubated for 20 hrs2022European journal of medicinal chemistry, Mar-05, Volume: 231Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID1872512Antifungal activity against Candida albicans TIMM1850 assessed as inhibition of fungal growth incubated for 20 hrs2022European journal of medicinal chemistry, Mar-05, Volume: 231Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID1759062Antifungal activity against Aspergillus fumigatus2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Microwave assisted regioselective synthesis of quinoline appended triazoles as potent anti-tubercular and antifungal agents via copper (I) catalyzed cycloaddition.
AID1872513Antifungal activity against Cryptococcus neoformans TIMM1740 assessed as inhibition of fungal growth incubated for 68 hrs2022European journal of medicinal chemistry, Mar-05, Volume: 231Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID1872517In vivo antifungal activity against Candida albicans infected in CDF1 mouse treated po 4 hrs after injection twice daily for 2 days measured on day 102022European journal of medicinal chemistry, Mar-05, Volume: 231Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID1872514Antifungal activity against Cryptococcus neoformans TIMM1855 assessed as inhibition of fungal growth incubated for 68 hrs2022European journal of medicinal chemistry, Mar-05, Volume: 231Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID1872505Antifungal activity against Candida albicans assessed as inhibition of fungal growth incubated for 20 hrs2022European journal of medicinal chemistry, Mar-05, Volume: 231Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID1872518In vivo antifungal activity against Aspergillus fumigatus infected in CDF1 mouse treated po 4 hrs after injection twice daily for 2 days measured on day 102022European journal of medicinal chemistry, Mar-05, Volume: 231Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
AID1872506In vivo antifungal activity against Candida albicans infected in CDF1 mouse treated po or iv immediately after infection measured on day 72022European journal of medicinal chemistry, Mar-05, Volume: 231Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (75.00)29.6817
2010's0 (0.00)24.3611
2020's2 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.74 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]